KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31
KAMADA LTD
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 11, 2026
$7.61−0.15 (-1.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 21.7
- Dividend yield
- –
Share price
+$0.86 (+12.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Ex-dividend
KAMADA LTD grew revenue 12.1% to $180.46M over the twelve months to Dec 31, 2025. Operating income rose 30.8% to $26.23M, moving the operating margin from 12.5% to 14.5%.
Revenue
$180.46M
+12.1% vs. a year earlier
Operating income
$26.23M
+30.8% vs. a year earlier
EPS, diluted
$0.35
+40.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 21.7
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $180.46M
- EPS, diluted
- $0.35
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$180.46M+12.1% YoY
Gross profit
$76.41M+9.2% YoY
Operating income
$26.23M+30.8% YoY
Net income
–
EPS, diluted
$0.35+40.0% YoY
Reported period